Our Clinical Studies

The results of 2 clinical studies we performed in our practice are described here.

The first study, enrolling both men and women (30 participants), 12 weeks in length, used the combination of medications Phentermine and Belviq (Lorcaserin HCL) coupled with a low-glycemic diet, exercise, and behavior modification. The mean weight loss over 12 weeks was 28 pounds (11.8% of original body weight). In addition to weight loss, a decrease in both systolic and diastolic blood pressure was noted.

The second study enrolling both men and women (95 participants) was also 12 weeks in length. It compared a very low calorie diet (VLCD) with a low-glycemic diet using the medication combination Phentermine and Belviq (Lorcaserin HCL). Regular exercise and behavior modification was part of both arms of the study. The mean weight loss in the VLCD group was 40 pounds (16.78 % of original body weight) compared to a 27 pound weight loss (11.8% of original body weight) in the low-glycemic diet with medication group. This study confirmed the weight loss seen in the original study of a low-glycemic diet and the use of the combination of Phentermine and Belviq.

Belviq (Lorcaserin HCL) + Phentermine Clinical Study

Click filename below to access file

Phen_-_Belviq_Study.pdf

VLCD vs Low-Glycemic Diet Clinical Study

Click filename below to access file

VLCD_vs_Low-Glycemic_Diet_Study.pdf